NEA et al. invest $33.1m in Ziarco

New backer Amgen Ventures and existing investors BVF Partners and Pfizer Venture Investments also took part in the round.

Ziarco will use the fresh capital to begin phase-II proof-of-concept studies for its two leading compounds, ZPL-389 and ZPL-521.

Previous funding
In November 2012, Pfizer and BVF injected £16.8m into Ziarco. BVF led the series-A round, according to unquote" data.

Company
Founded in 2012 and headquartered in Canterbury, Ziarca is clinical-stage biotech that focuses on developing therapies designed to treat inflammatory skin diseases.

Its two leading compounds are ZPL-389, a histamine for atopic dermatitis, and ZPL-521, a topical inhibitor for psoriasis and atopic dermatitis.

People
Mike Yeadon is the president and CEO of Ziarco. NEA partner Ed Mathers and Lundbeckfond senior partner Johan Kördel have joined the company's board of directors, which already includes BVF founder Mark Lampert. Mathers has become chairman of the board.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• UK / Ireland
• Healthcare
• United Kingdom